Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Researchers unravel how epithelial cells become invasive and cancerous

Epithelial cells, which line the surfaces and organs of the body, can protect themselves against cancer by removing unhealthy or abnormal cells through a mechanism known as "apical extrusion," where the damaged cells are forcibly removed from the cell layer by the surrounding healthy cells.

11 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Study finds above-average rates of mortality from gastric cancer in South Florida

South Florida counties have above-average rates of mortality from gastric cancer, according to a new study published in the journal Gastroenterology by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

29 Jun 2022

Discovery suggests a new way to slow or stop metastatic spread of pancreatic cancer

Pancreatic cancer, though rare, is one of the deadliest of cancers, killing nearly 50,000 people yearly and doing so quickly, primarily because it metastasizes rapidly through the body. Barely one in 10 people survive beyond five years.

29 Jun 2022

Researchers discover a molecular switch that promotes pancreatic cancer metastasis

More than 62,000 people in the United States will be diagnosed with pancreatic cancer by the end of this year, with the vast majority having a deadly and aggressive subtype known as pancreatic ductal adenocarcinoma (PDA).

27 Jun 2022

Erectile dysfunction drugs may be able to boost the effect of chemotherapy in esophageal cancer

A group of drugs commonly used to treat erectile dysfunction may be able to boost the effect of chemotherapy in esophageal cancer, according to new research funded by Cancer Research UK and the Medical Research Council.

21 Jun 2022

Chemical synthesis, properties, and molecular modeling studies of spiro-indole compounds

In a recent study under review at the Scientific Reports journal and currently posted to the Research Square* preprint server, researchers synthesized and evaluated the antitumoral (against several cancer cell lines) and antiviral [against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] properties of 3-spiro-indolin-2-ones.

15 Jun 2022

The potential mechanisms of SARS-CoV-2 to induce DNA damage

Researchers described potential mechanisms of coronaviruses that could lead to DNA damage and the potential link between SARS-CoV-2 activity and such mechanisms.

14 Jun 2022

Stress protein in fibroblasts appears to be an attractive cancer drug target

A stress protein that is overactive in many types of tumor cells also has a key role in tumor-supporting cells called fibroblasts, and may be a good target for future cancer treatments, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

10 Jun 2022

Research reveals why many cancers are vulnerable to FDA-approved IDH1 inhibitors

A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions.

9 Jun 2022

USA–Japan Workshop participants present cutting-edge research on biomarkers for early detection of cancer

Successful treatment of cancer frequently depends on early detection. However, many cancers are detected late, often after metastasizing to other sites.

9 Jun 2022

Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiation

Before a patient can undergo T cell therapy designed to target cancerous tumors, the patient's entire immune system must be destroyed with chemotherapy or radiation. The toxic side effects are well known, including nausea, extreme fatigue and hair loss.

8 Jun 2022

New FR-targeting, micropinocytosis-mediated bioconjugate attacks K-Ras mutant pancreatic cancer

Often undetected until it has progressed to an advanced stage, pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer.

6 Jun 2022

Chemo-immunotherapy combination shows promise against pancreatic cancer

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.

6 Jun 2022

New guidelines recommend pancreatic cancer screening for individuals with genetic susceptibility

By the year 2030, pancreatic cancer is expected to become the second most common cause of cancer deaths for both men and women in the United States, according to recent reports.

3 Jun 2022

Aerobic exercise amplifies the effects of immunotherapy to reduce pancreatic tumor growth

Aerobic exercise reprograms the immune system to reduce pancreatic tumor growth and amplify the effects of immunotherapy, a new study finds.

2 Jun 2022

Substances touted to improve athletic performance and high fat diet fuel pancreatic cancer’s development

Researchers at the University of Michigan Rogel Cancer Center have found a cell nuclear receptor activated by high fat diets and synthetic substances in unregulated athletic performance enhancers fuels the progression of precancerous pancreas lesions into pancreatic cancer.

1 Jun 2022

UCLA researchers identify a method to make tumors susceptible to immune attack

One powerful way cancer cells defend against tumor-killing immune cells is to load up their cell surface with a protein known as PD-L1. Now a team of UCLA Jonsson Comprehensive Cancer Center researchers led by Roger S. Lo, MD, PhD, has identified a method to degrade tumor cell-surface PD-L1, thereby making tumors susceptible to immune attack.

31 May 2022

Scientists develop new way to attack synovial sarcoma using an investigational drug

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma -; a rare tumor of soft tissues, such as ligaments and muscles -; using an investigational drug that triggers cell death.